Pharmacogenetics in clinical practice: considerations for testing

References

• Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin. Pharmacokinet. 40, 783–802 (2001).
   PubMed Web of Science ®Google Scholar
• Veenstra DL. Bringing genomics to the bedside: a cost-effective pharmacogenomic test? Pharmacogenetics 14, 333–334 (2004).
   PubMedGoogle Scholar
• Holtzman NA, Watson MS. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. J. Child. Fam. Nurs. 2(5), 388–390 (1999).
   Google Scholar
• National Screening Committeeof the United Kingdom. First Report of the National Screening Committee. Departments of Health, UK (1998).
   Google Scholar
• Walker MC, Johnson MR, Patsalos PN. Pharmacogenetic aspects. In: Antiepileptic drugs: Combination Therapy and Interactions. Majkowski J, Bourgeois B, Patsolos P, Mattson R (Eds), Cambridge University Press, Cambride, UK (2005).
   Google Scholar
• Muir Gray JA. 3.6 screening. In: Oxford Textbook of Medicine. 4th Ed. Warrell DA, Cox TN, Firth JD, Benz EJ (Eds), Oxford University Press, 68–73 (2003).
   Google Scholar
• Pirmohamed M, Ferner RE. Monitoring drug treatment. Br. Med. J. 327, 1179–1181 (2003).
   PubMedGoogle Scholar
• Hadow JE, Palomaki G. ACCE. Population-Based Pre-natal Screening for Cystic Fibrosis via Carrier Testing. Office of Genomics and Disease Prevention, CDC, USA (2002).
   Google Scholar
• Secretary’s AdvisoryCommittee on Genetic Testing. Enhancing the Oversight of Genetic Test. Recommendations of the SACGT. National Institutes of Health, MD, USA, 1–32 (2000).
   Google Scholar
• Secretary’s AdvisoryCommittee on Genetic Testing. Development of a Classification Methodology for Genetic Tests: Conclusions and Recommendations of the Secretary’s Advisory Committee on Genetic Testing. National Institutes of Health, MD, USA, 1–7 (2001).
   Google Scholar
• Burke W, Atkins D, Gwinn M et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am. J. Epidemiol. 156, 311–318 (2002).
   PubMedGoogle Scholar
• US Department of Healthand Human Services Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions. FDA, MD, USA (2005).
   Google Scholar
• Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat. Res. 573(1–2), 180–194 (2005).
   PubMed Web of Science ®Google Scholar
• Kroese M, Zimmern RL, Sanderson S. Genetic tests and their evaluation: can we answer the key questions? Genet. Med. 6, 475–480 (2004).
   PubMedGoogle Scholar
• Johnson MR, Good CD, Penny WD, Barnes PR, Scadding JW. Lesson of the week: playing the odds in clinical decision making: lessons from berry aneurysms undetected by magnetic resonance angiography. Br. Med. J. 322, 1347–1349 (2001).
   PubMedGoogle Scholar
• Palomaki GE, Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WW. Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing. Genet. Med. 5(6), 440–443 (2003).
   PubMedGoogle Scholar
• Begg CB, Greenes RA, Iglewicz B. The influence of uninterpretability on the assessment of diagnostic tests. J. Chronic Dis. 39(8), 575–584 (1986).
   PubMedGoogle Scholar
• Little J, Bradley L, Bray MS et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am. J. Epidemiol. 156(4), 300–310 (2002).
   PubMed Web of Science ®Google Scholar
• Chu K, Brown AF. Likelihood ratios increase diagnostic certainty in pulmonary embolism. Emerg. Med. Australas. 17(4), 322–329 (2005).
   PubMedGoogle Scholar
• Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59(21), 2061–2069 (2002).
   PubMed Web of Science ®Google Scholar
• Rothenberg KH. Genetic information and health insurance: state legislative approaches. J. Law Med. Ethics 23, 312–319 (1995).
   PubMed Web of Science ®Google Scholar
• Billings PR, Kohn MA, de Cuevas M et al. Discrimination as a consequence of genetic testing. Am. J. Hum. Genet. 50, 476–482 (1992).
   PubMed Web of Science ®Google Scholar
• Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. Science 274, 621–624.
   PubMedGoogle Scholar
• Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 18(4), 344–360 (2004).
   PubMedGoogle Scholar
• Shastry BS. Genetic diversity and new therapeutic concepts. J. Hum. Genetics 50, 321–328 (2005).
   PubMed Web of Science ®Google Scholar
• Mahlknecht U, Voelter-Mahlknecht S. Pharmacogenomics: questions and concerns. Curr. Med. Res. Opin. 21, 1041–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Morley KI, Hall WD. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. Mol. Med. 82, 21–30 (2004).
   Google Scholar
• Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).
   PubMed Web of Science ®Google Scholar
• Postma R, Schroder FH. Screening for prostate cancer. Eur. J. Cancer 41, 825–833 (2005).
   PubMed Web of Science ®Google Scholar
• Punglia RS, D’Amico AV, Catalona WJ et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N. Engl. J. Med. 349, 335–342 (2003).
   PubMedGoogle Scholar
• de Koning HJ, Auvinen A, Sanchez AB et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer Screening trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int. J. Cancer 97, 237–344 (2002).
   PubMed Web of Science ®Google Scholar
• Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int. J. Cancer 112, 357–364 (2004).
   PubMedGoogle Scholar
• Fodor FH, Weston A, Bleiweiss IJ et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet. 63, 45–51 (1998).
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336, 1401–1408 (1997).
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Struewing JP, Hartge P et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352, 1337–1339 (1998).
   PubMed Web of Science ®Google Scholar
• Taylor MR. Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician. Postgrad. Med. J. 77, 11–15 (2001).
   PubMedGoogle Scholar
• Burke W, Press NA, Pinsky LE. BRCA1 and BRCA2: a small part of the puzzle. J. Natl Cancer Inst. 91, 904–905 (1999).
   PubMedGoogle Scholar
• Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology – from West to the rest. Diabetes Care 15, 232–252 (1992).
   PubMed Web of Science ®Google Scholar
• Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362, 1275–1281 (2003).
   PubMed Web of Science ®Google Scholar
• Tattersall RB. Mild familial diabetes with dominant inheritance. Q. J. Med. 43, 339–357 (1974).
   PubMedGoogle Scholar
• Pearson ER, Velho G, Clark P et al. β-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations. Diabetes 50, S101–S107 (2001).
   PubMed Web of Science ®Google Scholar
• Frayling TM, Evans JC, Bulman MP et al. β-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50, S94–S100 (2001).
   PubMed Web of Science ®Google Scholar
• UK Prospective DiabetesStudy Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
   PubMedGoogle Scholar
• The Diabetes Controland Complications Trial Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–989 (1993).
   PubMedGoogle Scholar
• Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603–1614 (2001).
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Ziagen^® (Package insert). GlaxoSmithKline, NC, USA (2003).
   Google Scholar
• Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 13, 1419–1420 (1999).
   PubMed Web of Science ®Google Scholar
• Easterbrook PJ, Waters A, Murad S et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 4(4), 321–324 (2003).
   PubMedGoogle Scholar
• Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology 158, 11–23 (2001).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Park BK. HIV and drug allergy. Curr. Opin. Allergy Clin. Immunol. 1(4), 311–316 (2001).
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727–732 (2002).
   PubMed Web of Science ®Google Scholar
• Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin. Infect. Dis. 39(1), 98–106 (2004).
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121–1122 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335–342 (2004).
   PubMedGoogle Scholar
• Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180–4185 (2004).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Monitoring of AZA/6-MP treatment in children with IBD is necessary. Inflamm. Bowel Dis. 9(6), 386–388 (2003).
   PubMedGoogle Scholar
• Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenetics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118, 705–713 (2000).
   PubMed Web of Science ®Google Scholar
• Gaffney K, Scott DG. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br. J. Rheumatol. 37, 824–836 (1998).
   PubMedGoogle Scholar
• Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 43(1), 13–18 (2004).
   PubMed Web of Science ®Google Scholar
• Carette S, Klippel JH, Decker JL et al. Controlled studies on oral immunosuppressive drugs in lupus nephritis: a long-term follow-up. Ann. Intern. Med. 99, 1–8 (1983).
   PubMed Web of Science ®Google Scholar
• Smith NF, Figg WD, Sparreboom A. Recent advances in pharmacogenetic approaches to anticancer drug development. Drug Dev. Res. 62, 233–253 (2004).
   Web of Science ®Google Scholar
• GlaxoSmithKline. Imuran^® (Package insert). GlaxoSmithKline, UK (2003).
   Google Scholar
• Whisnant JK, Pelkey J. Rheumatoid arthritis: treatment with azathioprine (Imuran®). Clinical side effects and laboratory abnormalities. Ann. Rheum. Dis. 41(Suppl. 1), 44–47 (1982).
   PubMed Web of Science ®Google Scholar
• Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin. Pharmacol. Ther. 75, 274–281 (2004).
   PubMedGoogle Scholar
• Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329–339 (1992).
   PubMed Web of Science ®Google Scholar
• Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149–154 (1989).
   PubMed Web of Science ®Google Scholar
• Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225–229 (1990).
   PubMed Web of Science ®Google Scholar
• Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch. Dis. Child 69, 577–579 (1993).
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Srimarthpirom S, Reungjui S, Chansung K, Romphruk A. Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT* 1/*3C. Transplantation 76, 265–266 (2003).
   PubMed Web of Science ®Google Scholar
• Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2, 410–417 (2004).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122, 904–915 (2002).
   PubMed Web of Science ®Google Scholar
• Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukaemia. Blood 93, 2817–2823 (1999).
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651–662 (1980).
   PubMed Web of Science ®Google Scholar
• Tai HL, Krynetski EY, Yates CR et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58, 694–702 (1996).
   PubMed Web of Science ®Google Scholar
• Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Int. Med. 126, 608–614 (1997).
   PubMed Web of Science ®Google Scholar
• Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62, 60–73 (1997).
   PubMed Web of Science ®Google Scholar
• Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 43, 156–163 (2004).
   PubMed Web of Science ®Google Scholar
• Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29, 2507–2512 (2002).
   PubMed Web of Science ®Google Scholar
• Heckmann JM, Lambson EM, Little F, Owen EP. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J. Neurol. Sci. 231(1–2), 71–80 (2005).
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344, 1453–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Martinelli I. Pros and cons of thrombophilia testing: pros. J. Thromb. Haemost. 1, 410–411 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol. Sci. 16, 325–327 (1995).
   PubMed Web of Science ®Google Scholar
• Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19, 383–386 (2001).
   PubMed Web of Science ®Google Scholar
• van Ede E, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arth. Rheum. 44, 2525–2530 (2001).
   PubMed Web of Science ®Google Scholar
• Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12, 183–190 (2002).
   PubMedGoogle Scholar
• Chiusolo P, Reddiconto G, Casorelli I et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. 13, 1915–1918 (2002).
   PubMed Web of Science ®Google Scholar
• Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690–1698 (2002).
   PubMed Web of Science ®Google Scholar